✦ LIBER ✦

The efficacy and safety of chemotherapy in combination with bevacizumab vs. bevacizumab alone in recurrent epithelial ovarian cancer – A multi-institutional study

✍ Scribed by K. Fuh; A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; K. Bevis; A. ElNaggar; R. Previs; T. Kiet; J. Chan

Book ID: 113963789
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 69 KB
Volume: 125
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2011.12.234

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outcomes of ovarian cancer patients afte

Outcomes of ovarian cancer patients after bevacizumab and chemotherapy in primary vs. recurrent setting – A multi-institutional study

✍ J. Chan; A. Alvarez-Secord; T. Tillmanns; K. Moore; K. Bevis; A. ElNaggar; L. Pe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Prognostic factors predictive of respons

Prognostic factors predictive of response to bevacizumab combined with chemotherapy in recurrent ovarian cancer – A multi-institutional study

✍ A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; J. Chapman; C. McClung; T. Ki 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Factors predictive of toxicity associate

Factors predictive of toxicity associated with bevacizumab and chemotherapy in recurrent ovarian cancer: A multi-institutional study

✍ J. Chan; W. Huh; C. McClung; A. Alvarez-Secord; K. Moore; R. Previs; L. Perry; K 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 111 KB

The Efficacy and Toxicity of Bevacizumab

The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer

✍ Bevis, Kerri S.; Erwin, Jamie L.; Barnes, Mack N.; Straughn, J. Michael 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 172 KB

Phase II Study of Efficacy and Safety of

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer

✍ Herbst, R. S.; O'Neill, V. J.; Fehrenbacher, L.; Belani, C. P.; Bonomi, P. D.; H 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 144 KB

6084 Efficacy and safety of bevacizumab-

6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)

✍ Ducreux, M.; Adenis, A.; Pignon, J.P.; François, E.; Chauffert, B.; Boucher, E.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB